In our previous research, formononetin was found to exhibit anti-triple-negative breast cancer properties through the enhancement of the tumoricidal effect of everolimus via the inhibition of Akt activity (Li et al., 2021; Zhou et al., 2019), indicating its potential as a therapeutic agent for breast cancer inhibition. This evidence concerns the gene AKT1 and breast carcinoma.